

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Tylan G250 Premix for medicated feeding stuff for pigs, broilers and pullets

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

### Active substance:

Each kg contains 250g tylosin activity (as tylosin phosphate)

Qualitative composition of excipients and other constituents
Starch Pregelatinised
Soya Bean Feed Special (solvent extracted)

Light tan coloured, free flowing granular material.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Pigs, broilers and pullets.

### 3.2 Indications for use for each target species

Pigs:

For the prevention and control of enzootic pneumonia.

For the treatment and control of *Lawsonia intracellularis*, the organism associated with Porcine Intestinal Adenomatosis (Ileitis) and Porcine Haemorrhagic Enteropathy.

Broilers and pullets:

Treatment and prevention of respiratory infections caused by *Mycoplasma gallisepticum* and *Mycoplasma synoviae*, when the disease has been diagnosed in the flock.

Treatment and prevention of necrotic enteritis caused by *Clostridium perfringens*, when the disease has been diagnosed in the flock.

The presence of the disease in the group or flock must be established before the product is used.

### 3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals vaccinated with tylosin-sensitive vaccines either at the same time or within one week previously.

### 3.4 Special warnings

None.

### 3.5 Special precautions for use

Use of the product should be in accordance with official, national and regional antimicrobial policies.

Special precautions for safe use in the target species:

For incorporation into medicated feedingstuffs only.

To ensure thorough dispersion of the product it should first be mixed with a small quantity of feed ingredients before incorporation into the final mix.

Use of the product should be based on identification and susceptibility testing of the target pathogen(s). If this is not possible, therapy should be based on epidemiological information and knowledge of susceptibility of the target pathogens at farm level, or at local/regional level.

An antibiotic with a lower risk of antimicrobial resistance selection (lower AMEG category) should be used for first line treatment where susceptibility testing suggests the likely efficacy of this approach.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Tylosin may induce irritation. Macrolides, such as tylosin, may also cause hypersensitivity (allergy) following injection, inhalation, ingestion or contact with skin or eye. Hypersensitivity to tylosin may lead to cross reactions to other macrolides and vice versa. Allergic reactions to these substances may occasionally be serious and therefore direct contact should be avoided.

To avoid exposure during preparation of the medicated feed, wear overalls, safety glasses, impervious gloves and wear either a disposable half mask respirator conforming to European Standard EN149 or a non-disposable respirator to European Standard EN140 with a filter to EN143. Wash hands after use. In the event of accidental skin contact, wash thoroughly with soap and water. In case of accidental eye contact, flush the eyes with plenty of clean, running water.

Do not handle the product if you are allergic to ingredients in the product.

If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the package leaflet or the label to the physician. Swelling of the face, lips and eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.

Special precautions for the protection of the environment:

Not applicable.

### **3.6 Adverse events**

Pigs, broilers and pullets:

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the label for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

Pregnancy and lactation:

No studies have been conducted in the target species population. Use only according to the benefit risk assessment by the responsible veterinarian.

### **3.8 Interaction with other medicinal products and other forms of interaction**

Lincosamides and aminoglycoside antibiotics antagonise the activity of tylosin.

### **3.9 Administration routes and dosage**

For incorporation into dry feed at the registered mill.

A manufacturer who is approved to incorporate directly at any concentration, veterinary medicinal products or premixtures containing such products must be responsible for mixing when incorporation is less than 2 kg per tonne for final feed.

For oral administration.

### **Pigs:**

*Prevention and control of enzootic pneumonia:*

3-6 mg tylosin activity/kg bodyweight, which may normally be achieved by adding the product at the rate of 400 g per tonne, giving 100 g tylosin base per tonne. Feed as the only ration for 21 days.

*Treatment and control of Lawsonia intracellularis:*

3-6 mg tylosin activity/kg bodyweight, which may normally be achieved by adding the product at the rate of 400 g per tonne, giving 100 g tylosin base per tonne. Feed as the only ration for 21 days.

The required levels of tylosin are obtained by mixing the appropriate quantity of the veterinary medicinal product with 20-50 kg of a suitable feed component, prior to incorporation into the bulk of the feed to be prepared.

### **Broilers and pullets:**

*For the treatment and prevention of respiratory infections:*

127 mg tylosin per kg bodyweight (corresponding to 508 mg of the veterinary medicinal product per kg bodyweight) for the first 5 days of life. It is strongly recommended to repeat the treatment of the birds at the age of 3-4 weeks.

*For the treatment and prevention of necrotic enteritis:*

10 - 20 mg tylosin per kg bodyweight (corresponding to 40 - 80 mg of the veterinary medicinal product per kg bodyweight) for 7 days.

For the preparation of the medicated feed the body weight of the animals to be treated and their actual daily feed consumption should be taken into due account. Consumption may vary depending on factors like age, breed, husbandry system. To provide the required amount of active substance in mg per kg mixed feed the following calculation should be made:

$$\frac{\text{.... mg veterinary medicinal product / kg bodyweight/day}}{\text{average daily amount of mixed feed intake /kg per animal}} \times \text{average body weight (kg) of animals to be treated} = \text{... mg veterinary medicinal product per kg of mixed feed}$$

The intake of medicated feed depends on the clinical condition of the animals. In order to obtain the correct dosage, the concentration of the veterinary medicinal product has to be adjusted accordingly.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

The veterinary medicinal product has been shown to produce no adverse effects when fed to pigs at 600 ppm in the feed (six times the recommended maximum level) for 28 days.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Meat and offal:  
Pigs: Zero days.  
Broilers and pullets: 1 day  
Do not use in laying hens producing eggs for human consumption.

#### **4. PHARMACOLOGICAL INFORMATION**

##### **4.1 ATCvet code: QJ01FA90**

##### **4.2 Pharmacodynamics**

Tylosin is a macrolide antibiotic produced by a strain of *Streptomyces fradiae*. It exerts its antimicrobial effect by inhibiting protein synthesis of susceptible micro-organisms. The tylosin spectrum of activity includes Gram-positive bacteria, some Gram-negative strains such as *Pasteurella* and *Mycoplasma* spp at concentrations of 16µg/ml or less.

##### **4.3 Pharmacokinetics**

Absorption: Tylosin reaches maximal blood levels between 1 and 3 hours after an oral dose. Minimal or no blood levels remain 24 hours after an oral dose.

Distribution: After oral doses were given to pigs, tylosin was found in all tissues, between 30 minutes and two hours after administration, except for the brain and spinal cord.

Biotransformation and Elimination: It has been shown that most of the material which is excreted is to be found in the faeces and consists of tylosin (factor A), relomycin (factor D) and dihydrodesmycosin.

#### **5. PHARMACEUTICAL PARTICULARS**

##### **5.1 Major incompatibilities**

None known.

##### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.  
Shelf life after incorporation into meal or pelleted feed: 3 months.

##### **5.3 Special precautions for storage**

Bag (i) (3-ply kraft paper sack) Do not store above 25°C. Store in a dry place.  
Bag (ii) (multiwalled sack). Do not store above 30°C. Store in a dry place.

The product will remain stable in finished feed for three months when stored below 25°C.

##### **5.4 Nature and composition of immediate packaging**

25kg 3-ply kraft paper sack, middle ply having an extrusion coating of low density polyethylene, stitched with tape and jute/cord filler.

25kg multiwalled sack comprising three layers (outer: bleached kraft paper, mid: kraft paper and inner: kraft paper, low density polythene, aluminium foil, low density polyethylene), with heat sealed closure.

##### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Elanco GmbH

**7. MARKETING AUTHORISATION NUMBER(S)**

VPA22020/034/002

**8. DATE OF FIRST AUTHORISATION**

14/05/1999

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

15/04/2024

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).